Materializing the Potential of Small Interfering RNA via a Tumor-Targeting Nanodelivery System

Pirollo, Kathleen F.; Rait, Antonina; Zhou, Qi; Hwang, Sung Hee; Dagata, John A.; Zon, Gerald; Hogrefe, Richard I.; Palchik, Guillermo; Chang, Esther H.

doi:10.1158/0008-5472.can-06-4535

Cited by 183 publications

(141 citation statements)

References 28 publications

Supporting

Mentioning

139

Contrasting

Order By: Relevance

“…Tf-and TfR-scFv-targeted nanovectors were recently approved by the FDA for clinical testing, and the first Phase-I clinical trial for non-viral systemic p53 gene therapy is ongoing (www.ClinicalTrials.gov). The success of these nanovectors for systemic p53 gene therapy, and more recently Her-2 siRNA therapy (96)(97)(98), provide a promising, tumor-targeted delivery system for novel RNAi-based therapies, such as miRNA-therapeutics discussed above.…”

Section: Microrna Therapeuticsmentioning

confidence: 99%

MicroRNA Regulation of Cancer Stem Cells and Therapeutic Implications

DeSano

2009

AAPS J

143

107

View full text Add to dashboard Cite

Abstract. MicroRNAs (miRNAs) are a class of endogenous non-protein-coding RNAs that function as important regulatory molecules by negatively regulating gene and protein expression via the RNA interference (RNAi) machinery. MiRNAs have been implicated to control a variety of cellular, physiological, and developmental processes. Aberrant expressions of miRNAs are connected to human diseases such as cancer. Cancer stem cells are a small subpopulation of cells identified in a variety of tumors that are capable of self-renewal and differentiation. Dysregulation of stem cell self-renewal is a likely requirement for the initiation and formation of cancer. Furthermore, cancer stem cells are a very likely cause of resistance to current cancer treatments, as well as relapse in cancer patients. Understanding the biology and pathways involved with cancer stem cells offers great promise for developing better cancer therapies, and might one day even provide a cure for cancer. Emerging evidence demonstrates that miRNAs are involved in cancer stem cell dysregulation. Recent studies also suggest that miRNAs play a critical role in carcinogenesis and oncogenesis by regulating cell proliferation and apoptosis as oncogenes or tumor suppressors, respectively. Therefore, molecularly targeted miRNA therapy could be a powerful tool to correct the cancer stem cell dysregulation.

show abstract

Section: Microrna Therapeuticsmentioning

confidence: 99%

MicroRNA Regulation of Cancer Stem Cells and Therapeutic Implications

DeSano

2009

AAPS J

143

107

View full text Add to dashboard Cite

show abstract

“…Liposomes encapsulating Her2 siRNAs with histadine-lysine peptides that facilitate endosomal release were targeted to prostate cancer xenografts by incorporating an scFv to the Tf receptor, whose expression is increased on the membranes of tumor cells. 63 …”

Section: Introductionmentioning

confidence: 99%

Special delivery: targeted therapy with small RNAs

2011

View full text Add to dashboard Cite

Harnessing RNA interference using small RNA-based drugs has great potential to develop drugs designed to knock down expression of any disease-causing gene, thereby greatly expanding the universe of possible drug targets. However, delivering small RNAs into specific tissues and cells is still a hurdle. Here, we review recent progress in overcoming systemic, local and cellular barriers to RNA drug delivery, focusing on strategies for targeted uptake.

show abstract

“…Even they do not effect on tumor tissue directly, so Immuno-liposomes are called antibody direct liposomes. Anti-transferrin receptor single-chain antibody fragment (TfRscFv) immune-liposomes have been established and certified great effectiveness in systemic gene therapy for pancreatic cancer [34][35][36].…”

Section: Immuno-liposome Based Targeted Drug Deliverymentioning

confidence: 99%

Liposomes and Nanotechnology in Drug Development: Focus On Pancreatic Cancer

Malik¹,

Jin²,

Raheem³

et al. 2017

JGPLD

View full text Add to dashboard Cite

Pancreatic cancer usually has high morbidity and mortality and rests one of the most challenging cancers to treat. 5 years survival rate is less than 6 percent overall for people with pancreatic cancer, because of very late diagnosis and absence of effective treatment. In a western world, pancreatic tumor is the fourth most common cause of death in a western world. The pancreatic tumor needs selective delivery of drugs to target cells, with no side effects is major goals of the recent investigations for the real treatment of the pancreatic tumor. Medication which targets pancreatic tumor cells specially and carriers which deliver medications to specific cells which are quickly dividing, development of these kind drugs is considered as magic for the management of pancreatic cancer. In latest years, liposomes and nanotechnology can show a vital character in the treatment of pancreatic tumor. Liposomes contain multiple characteristics, such as the ability to protect the material from degradation, the capacity for encapsulating many materials and capability for delivering materials intracellularly fusion with plasma membrane. Nanoparticles as a carrier offer a new style of delivery of the medications to target cells of a tumor and allow drugs for the binding to tumor cell membrane, to cytoplasmic and to nuclear receptor sites. It delivers high medication concentrations to specific cells with few side effects to other normal tissues. The general importance of this evaluation is to increase overall understanding of development of the therapeutic nanomedicine for the treatment of pancreatic tumors, agents delivered by nanoliposomes, liposomal nanomedicine in targeting cancer and safety issues.

show abstract

Materializing the Potential of Small Interfering RNA via a Tumor-Targeting Nanodelivery System

Abstract: The field of small interfering RNA (siRNA) as potent sequence-

Cited by 183 publications

References 28 publications

MicroRNA Regulation of Cancer Stem Cells and Therapeutic Implications

MicroRNA Regulation of Cancer Stem Cells and Therapeutic Implications

Special delivery: targeted therapy with small RNAs

Liposomes and Nanotechnology in Drug Development: Focus On Pancreatic Cancer

Contact Info

Product

Resources

About